

2014 - **Rainer Storb, MD**, Director, Transplantation Biology Program, Fred Hutchinson Cancer Research Center
“Allogeneic Hematopoietic Cell Transplantation”

2015 - **Stephen J. Forman, MD**, Chair, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center
“Development of a CMV Vaccine as an Antiviral and Anti-Leukemia Therapy”

Third Annual Karl G. Blume, MD Memorial Lecture

Nelson J. Chao, MD, MBA

Professor, Cancer Research, Medicine & Immunology
Chief, Division of Hematologic Malignancies
Chief, Division of Cellular Therapy/BMT
Duke University, Durham, NC

*“Hematopoietic Cell Transplantation:
From the Bubble Boy to Home Transplants”*


**Wednesday, April 6, 2016
8:00am**

Li Ka Shing Center for Learning and Knowledge
Stanford, CA

The **Karl G. Blume, M.D., Memorial Lectureship** is supported by the Stanford University School of Medicine - Department of Medicine, the Blume Lectureship Fund, Division of Blood and Marrow Transplantation, and Stanford Health Care. For information on contributing to the Blume Lectureship Fund please contact Laura Adams, laadams@stanforhealthcare.org, or 650.723.0822.

Introductions:
Robert S. Negrin, MD
Professor of Medicine,
Stanford University School of Medicine

Karl G. Blume, M.D.



1937-2013

Karl Georg Blume, M.D., was born in Germany on April 10, 1937. He completed his education at the University of Freiburg followed by residency and two fellowships, one in Freiburg and a second at City of Hope, National Medical Center in Duarte, California.


His mentor, Ernest Beutler, M.D., recruited him to establish an allogeneic transplant program at the City of Hope, where the first transplant was performed in May 1976.

Stanley Schrier, M.D., and Ronald Levy, M.D., recruited Karl to Stanford to start his second transplant program, and he and his team performed Stanford's first transplant on November 2, 1987. Since then over 6,000 patients have received transplants from the Stanford BMT Program, and today the team provides transplants to over 350 adult patients each year. The Stanford program is nationally recognized for both excellent patient care and its significant contributions to the science of blood and marrow transplantation.

Karl's influences on those who knew him are indelible. He had a remarkable talent for building and supporting a team that focused their talents above all on the patient and family, and also on the problems of graft-versus-host disease, infections, and transplant survivors' quality of life. He recognized the value and distinct contributions of each discipline that comprises a multidisciplinary team; understanding that the whole is greater than the sum of its individual members.

While he left behind a lifetime of vast accomplishment, he was perhaps most impressive in his unique abilities to make each person feel special, and to inspire others to excel. He is remembered for his many professional achievements, mentorship, visionary leadership, friendship, joie de vivre, and deep commitment to patients and to his family including his beloved wife, Vera, children Caroline and Philipp, and five grandchildren.

Nelson J. Chao, M.D.



Nelson J. Chao, M.D.

*Donald D. & Elizabeth G. Cooke, Professor
in Cancer Research
Professor of Medicine & Immunology
Chief,
Division of Hematological Malignancies
Division of Cellular Therapy/BMT*

Nelson J. Chao, MD, MBA, is the Donald D. and Elizabeth G. Cooke Professor in Cancer Research, Professor of Medicine and Immunology, and the Chief of the Division of Hematological Malignancies and the Division of Cellular Therapy/BMT at Duke University. He received his undergraduate degree from Harvard University, his MD from Yale University and his post-graduate training was completed at Stanford University.

He was the Associate Director of the Bone Marrow Transplant Program at Stanford prior to moving to Duke University in 1996 as the Director of the Bone Marrow Transplantation Program. Dr. Chao is also the Co-Director of the Clinical Stem Cell Transplantation Laboratory and continues to direct his own research laboratory focused on understanding and preventing graft-versus-host disease and improving immune reconstitution. Additionally, he serves as the Director of Global Cancer for the Duke Cancer Institute and the Duke Global Health Institute, and in 2012 became the Chief of the Division of Hematological Malignancies.

He obtained his MBA from the Fuqua School of Business at Duke University in 2000. He is the author of approximately 250 peer-reviewed papers, 25 book chapters and one book. He is also a co-founder of two start-up biotechnology companies in Research Triangle Park, Aldagen and C2 Regenerate. Nationally, he is the co-chair of the Radiation Injury Treatment Network (RITN) and the principal investigator for a Center for Medical Countermeasures against Radiation (CMCR).